Think of Sulfonylureas as CV Neutral

New evidence will provide more reassurance about the cardiovascular safety of sulfonylureas (glimepiride, etc) for type 2 diabetes.

There's been debate for years over whether sulfonylureas increase CV risk...mainly due to data with the old, first-generation tolbutamide.

To date, all sulfonylurea med labels warn of increased CV mortality.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals